[Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma].
BACKGROUND
Paclitaxel-carboplatin combination chemotherapy has been administered worldwide in the first-line adjuvant treatment of epithelial ovarian cancers since the mid 1990's.


OBJECTIVE
Goal was to evaluate the early results of the first-line paclitaxel-carboplatin treatment practiced at the Gynecological Department of National Institute of Oncology, Budapest between November 2000 and August 2002.


METHODS
Paclitaxel and carboplatin were administered in the doses of 175 mg/m2/3 h and AUC 5, respectively. Average age of patients was 54 +/- 9.8 years. The patients were considered into stage I in 18.4% and in stage II-III and IV in 4.6%, 52.9% and 8%. The surgeon did not reported the stage in 16.1% of patients. Statistical analysis was performed by the product limit method of Kaplan and Meier.


RESULTS
The progression free interval was found to be 100%, 50%, 71.7% and 71.4% in stages I, II, III and IV, at the end of the 6th chemotherapy course and decreased to 100%, 50%, 52.2% and 42.9% in the same stages at the time of evaluation (16 December 2002). Authors found a 77% CR in the patients at the end of chemotherapy.


CONCLUSIONS
Only progression free interval till the end of treatment could be evaluated because of the short follow up period. The observed 77% CR is similar to the data of the literature. The final conclusions will be made by later follow up.
Lehoczky
Ottó
O
Országos Onkológiai Intézet, Nógyógyászati Osztálya, Budapest. lehoczky@oncol.hu
Pulay
Tamás
T
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
D016190:Carboplatin; D017239:Paclitaxel